EMA Accepts Teva’s Olanzapine LAI Application for Schizophrenia Treatment

Event summary

  • The European Medicines Agency (EMA) accepted Teva’s Marketing Authorization Application for olanzapine long-acting injectable (TEV-‘749) for treating schizophrenia in adults.
  • TEV-‘749 uses Medincell’s SteadyTeq™ technology for controlled, prolonged drug release.
  • The submission is supported by the Phase 3 SOLARIS study, demonstrating efficacy and safety.
  • Schizophrenia affects 0.3–1.5% of Europe’s population, with treatment adherence being a significant challenge.

The big picture

The EMA’s acceptance of Teva’s application for olanzapine LAI marks a strategic step in addressing treatment adherence challenges in schizophrenia. This move aligns with broader industry trends toward long-acting injectables for mental health conditions, aiming to reduce relapse rates and improve patient outcomes. The success of TEV-‘749 could influence future developments in psychiatric drug formulations.

What we're watching

Regulatory Approval
Whether the EMA will grant approval for TEV-‘749, potentially expanding treatment options for schizophrenia patients in Europe.
Market Penetration
The pace at which TEV-‘749 can gain market share against existing long-acting injectables for schizophrenia.
Commercialization Strategy
How Teva and Medincell will position TEV-‘749 in the competitive European schizophrenia treatment landscape.